SAN DIEGO, CA, USA I August 18, 2025 I Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based ...

Filings both for the obicetrapib monotherapy and obicetrapib plus ezetimibe fixed-dose combination submitted to EMA by our partner, Menarini, for treatment ...

Melanocortin receptor agonists offer a promising, differentiated mechanism that targets key drivers of retinal diseases, including DR.

NEEDHAM, MA, USA I August 18, 2025 I Stealth BioTherapeutics, a clinical-stage biotechnology company focused on the discovery, development and ...

HANGZHOU, China I August 18, 2025 I Hangzhou Qihan Biotech Co., Ltd. ("Qihan" or "Qihan Biotech" or "the Company"), an industry leader in applying ...

OGSIVEO is the first and only therapy to receive marketing authorization in the EU for the treatment of desmoid tumors ...

NEWPORT BEACH, CA, USA I August 18, 2025 I jCyte, Inc. is pleased to announce the first patients have been enrolled and treated in the JC02-88 study ...

RESEARCH TRIANGLE PARK, NC, USA I August 18, 2025 I Opus Genetics (Nasdaq: IRD), a clinical-stage biopharmaceutical company developing gene therapies for the treatment of inherited retinal diseases ...

ROCKVILLE, MD, USA and SUZHOU, China I August 17, 2025 I Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical ...

NEW YORK, NY, USA I August 15, 2025 I Pfizer Inc. (NYSE: PFE) today announced results from the Phase 3 THRIVE-131 study evaluating inclacumab, an ...

SÖDERTÄLJE, Sweden I August 18, 2025 I Anocca AB (‘Anocca’ or the ‘Company’), a leading clinical-stage T-cell immunotherapy company, has successfully raised ...

CHATHAM, NJ, USA I August 15, 2025 I Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...